Amgen
Also known as: Amgen | AMGEN | Amgen Astellas Biopharma K.K. | Amgen Europe B.V | Amgen Inc. | AMGEN INC | Amgen Pharma, Munich | Amgen Research (Munich) GmbH | One Amgen Center Drive | ONYX PHARMS AMGEN | Prof. Kristian Reich | Stemgen
Highest phase reached
Phase 4
First clinical trial
Oct 1, 1994First marketed drug
Jun 1, 1989First NDA
Jun 1, 1989Last known activity
Jul 31, 2026
Timeline
1980s
- Jan 1, 1985
Amgen— Founded
1990s
- Jan 1, 1994
Synergen— Acquired
2000s
- Jan 1, 2002
Immunex— Acquired
- Jan 1, 2004
Tularik— Acquired
- Jan 1, 2005
Abgenix— Acquired
- Jan 1, 2007
Alantos Pharmaceuticals— Acquired
- Jan 1, 2007
Ilypsa— Acquired
- Jan 1, 2008
Avidia— Acquired
- Aug 22, 2008
romiplostim— Marketing Organization
- Aug 22, 2008
romiplostim— NDA Organization
2010s
- Jan 1, 2011
BioVex— Acquired
- Jan 1, 2012
deCODE genetics— Acquired
- Jan 1, 2012
KAI Pharmaceuticals— Acquired
- Jan 1, 2012
Micromet— Acquired
- Jan 1, 2012
Mustafa Nevzat Pharmaceuticals— Acquired
- Apr 11, 2012
- Apr 25, 2012
MN Pharmaceuticals— Acquired
- Jan 1, 2013
Onyx— Acquired
- Jan 1, 2015
Catherex— Acquired
- Jan 1, 2015
Dezima Pharmaceuticals— Acquired
- Jun 1, 2017
Celimmune— Acquired
- May 22, 2019
Nuevolution— Acquired
- Dec 6, 2019
infliximab— NDA Secondary Org
2020s
- Mar 4, 2021
Five Prime Therapeutics— Acquired
- Mar 31, 2021
Rodeo Therapeutics— Acquired
- Jul 28, 2021
Teneobio, Inc.— Acquired
- Aug 4, 2022
ChemoCentryx— Acquired
- Dec 12, 2022
Horizon Therapeutics, LLC— Acquired
Drugs by trial phase (391 distinct, 1465 trials)
Phase 4 (24 own, 21 via acquisition)
Phase 3 (65 own, 35 via acquisition)
Phase 2 (100 own, 40 via acquisition)
Phase 1 (88 own, 16 via acquisition)
Other trials (1 own, 1 via acquisition)
Indications
Approved for
Studied for
- Acquired Immunodeficiency Syndrome
- Acute Coronary Syndrome
- Adenocarcinoma
- Adenocarcinoma, Mucinous
- Adenocarcinoma of Lung
- Adenoma
- Adenoma, Islet Cell
- Adenoma, Pleomorphic
- Aggression
- AIDS-Related Complex
- Alzheimer Disease
- Amenorrhea
- Amyloidosis
- Anemia
- Anemia, Aplastic
- Angina Pectoris
- Angina, Stable
- Anorexia
- Anorexia Nervosa
- Anus Neoplasms
- Arthritis
- Arthritis, Juvenile
- Arthritis, Psoriatic
- Arthritis, Rheumatoid
- Asthma
- Astrocytoma
- Atherosclerosis
- Autonomic Nervous System Diseases
- Behcet Syndrome
- Biliary Tract Neoplasms
- Blast Crisis
- Bone Cysts
- Bone Cysts, Aneurysmal
- Bone Diseases
- Bone Diseases, Metabolic
- Bone Marrow Diseases
- Bone Neoplasms
- Brain Concussion
- Brain Injuries
- Brain Injuries, Traumatic
- Breast Neoplasms
- Bronchial Diseases
- Burkitt Lymphoma
- Calcinosis
- Carcinoid Tumor
- Carcinoma
- Carcinoma, Ductal
- Carcinoma, Ductal, Breast
- Carcinoma, Hepatocellular
- Carcinoma, Merkel Cell
- Carcinoma, Neuroendocrine
- Carcinoma, Non-Small-Cell Lung
- Carcinoma, Ovarian Epithelial
- Carcinoma, Renal Cell
- Carcinoma, Squamous Cell
- Carcinoma, Transitional Cell
- Cardiovascular Diseases
- Carotid Stenosis
- Cataract
- Chondroblastoma
- Chronic Kidney Disease-Mineral and Bone Disorder
- Chronic Pain
- Colitis
- Colitis, Ulcerative
- Colonic Neoplasms
- Colorectal Neoplasms
- Communicable Diseases
- Constriction, Pathologic
- Coronary Artery Disease
- Coronary Disease
- Crohn Disease
- Cystadenocarcinoma
- Deglutition Disorders
- Dermatitis
- Dermatitis, Atopic
- Dermatomyositis
- Desmoplastic Small Round Cell Tumor
- Diabetes Mellitus
- Diabetes Mellitus, Type 1
- Diabetes Mellitus, Type 2
- Disease
- Dyslipidemias
- Eczema
- Endocrine Gland Neoplasms
- Erectile Dysfunction
- Erythema
- Esophageal Neoplasms
- Esophageal Squamous Cell Carcinoma
- Exanthema
- Facial Pain
- Facies
- Fallopian Tube Neoplasms
- Feeding and Eating Disorders
- Fibroma
- Fractures, Bone
- Gallbladder Neoplasms
- Gastrointestinal Neoplasms
- Gastrointestinal Stromal Tumors
- Genital Neoplasms, Female
- Giant Cell Tumor of Bone
Marketed drugs (28)
Subsidiaries (25 direct, 42 total across the full acquisition tree)
- Abgenix
- Alantos Pharmaceuticals
- Avidia
- BioVex
- Catherex
- Celimmune
- ChemoCentryx
- deCODE genetics
- Dezima Pharmaceuticals
- Five Prime Therapeutics
- Horizon Pharma
- Horizon Therapeutics, LLC
- Ilypsa
- Immunex
- KAI Pharmaceuticals
- Laboratório Químico Farmacêutico Bergamo Ltda.
- Micromet
- MN Pharmaceuticals
- Mustafa Nevzat Pharmaceuticals
- Nuevolution
- Onyx
- Rodeo Therapeutics
- Synergen
- Teneobio, Inc.
- Tularik
- CancerVax Corporation L2
- Crealta L2
- Hyperion Therapeutics L2
- Immgenics L2
- IntraImmune Therapies L2
- Nitec Pharma AG L2
- Proteolix L2
- Raptor Pharmaceuticals Corp. L2
- River Vision Development Corporation L2
- Vidara Therapeutics L2
- Viela Bio L2
- AGI Therapeutics, Inc. L3
- Andromeda Biotech Ltd. L3
- Cell-Matrix L3
- Savient Pharmaceuticals L3
- TorreyPines Therapeutics L3
- Gynex L4
Recent trials (50)
- NCT04667234Lead sponsorN/A—
- NCT04667234Study directorN/A—
- NCT05256446Lead sponsorN/A—
- NCT05256446Study directorN/A—
- NCT06064500Lead sponsorN/A—
- NCT06064500Study directorN/A—
- NCT07079267Lead sponsorN/A—
- NCT03439475Lead sponsorN/A—
- NCT07176546CollaboratorPhase 2/Phase 3Jul 31, 2026
- NCT07203053CollaboratorPhase 2May 31, 2026
- NCT07283640CollaboratorPhase 1May 18, 2026
- NCT06987539Lead sponsorPhase 2Apr 30, 2026
- NCT06987539OfficialPhase 2Apr 30, 2026
- NCT07293260Lead sponsorPhase 3Mar 21, 2026
- NCT07293260OfficialPhase 3Mar 21, 2026
Details
- Founded
- Thousand Oaks, CA, US Jan 1, 1985
- First NDA
- Jun 1, 1989
- Last known activity
- Jul 31, 2026
Designations held
- Orphan drug
- Fast track
- Priority review
- Breakthrough therapy
- Accelerated approval